Cibeles

Pune, India
Pharmaceutical manufacturing, distribution, and employee-focused services in India.

About Cibeles

Cibeles is a Healthcare company based in Pune (India). Pharmaceutical manufacturing, distribution, and employee-focused services in India. It operates in the Healthcare and Transportation, Automotive & Logistics sectors. Its Indian entity Cibeles Pharmaceuticals Private Limited reported revenue of β‚Ή27.15 Cr. Cibeles offers products and services including Pharmaceutical Products and Distribution Services. Its focus areas include Pharmaceuticals, Drug Manufacturing, Women's Health Products and Distribution.

Company details

Cibeles Pharmaceuticals Private Limited is observed as an organization that prioritizes people in its operations, fostering a caring and inclusive culture where employees, referred to as Cibeleans, are provided opportunities for growth and meaningful work. Relationships with trade partners are built to ensure sustainable collaborations for patient access to solutions. Innovation is pursued to expand offerings, benefiting stakeholders and contributing to broader societal advancement. The company is noted for its commitment to womens health and internal achievements, operating from Pune, India, with a focus on ethical practices and career development.

  • Headquarters Pune, India
  • Sectors
    Healthcare
    Transportation, Automotive & Logistics
  • Email
    β€’β€’β€’β€’β€’β€’β€’β€’
  • Website cibeles.com
  • Social LinkedIn
  • Legal Name Cibeles Pharmaceuticals Private Limited
  • Date of Incorporation 03 May, 2019
  • Jurisdiction Mumbai, Maharashtra, India
Key Metrics
  • Annual Revenue
    ₹27.15 Cr

    FY 2025 · +48% YoY

  • Net Loss
    -₹9.15 Cr

    FY 2025 · -34% margin

  • EBITDA
    -₹9.20 Cr

    FY 2025 · -34% margin

Products & Services of Cibeles

Cibeles offers a comprehensive portfolio of products and services, including Pharmaceutical Products and Distribution Services.

Pharmaceutical Products
Healthcare Solutions

Pharmaceutical products are developed and distributed by Cibeles to address women's health and other needs, ensuring access through partnerships.

Distribution Services
Supply Chain

Distribution services are managed by Cibeles to facilitate collaborations with trade partners for timely delivery of solutions.

Board of directors of Cibeles Pharmaceuticals Private Limited (Cibeles)

Cibeles Pharmaceuticals Private Limited is the primary company behind Cibeles. The board of Cibeles Pharmaceuticals Private Limited currently have 3 directors; the longest-serving is Sainath Vramarathnam Iyer, appointed in 2019. 4 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Sainath Vramarathnam Iyer
DIN 08590081
Director22 Oct 20197 yrsCibeles Pharmaceuticals Private Limited
Trushit Pramodray Mehta
DIN 06439479
Nominee Director03 Mar 20206 yrs 8 moCibeles Pharmaceuticals Private Limited
Dheer Dharmesh Shah
DIN 07937075
Nominee Director03 Mar 20206 yrs 8 moCibeles Pharmaceuticals Private Limited

Financials of Cibeles

Figures of Cibeles Pharmaceuticals Private Limited, the primary company behind Cibeles, for FY 2025. Revenue was ₹27.15 Cr (+48% year on year). Net loss was -₹9.15 Cr (-34% margin). EBITDA was -₹9.20 Cr (-34% margin). Revenue has grown at a compounded annual rate of +35% over three years and +109% over five years.

  • ₹27.15 CrRevenue · FY 2025 · +48% YoY
  • -₹9.15 CrNet loss · -34% margin
  • -₹9.20 CrEBITDA · -34% margin
  • ₹22.32 CrPaid-up capital
  • +35%Revenue CAGR, 3 years
  • +109%Revenue CAGR, 5 years

Balance sheet, profit and loss, cash flow and ratios of Cibeles Pharmaceuticals Private Limited are on its company page.

Premium access

Detailed financial statements for Cibeles

Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.

  • Statement rows
  • Financial ratios
  • Five-year trends
  • Downloads

Verified entity values are shown only after access is granted.

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Frequently Asked Questions about Cibeles

Cibeles is headquartered in Pune, India. It is registered at Pune, Maharashtra, India.

The primary company behind Cibeles, Cibeles Pharmaceuticals Private Limited, reported revenue of β‚Ή27.15 Cr for FY 2025, up 48% year on year.

Cibeles Pharmaceuticals Private Limited is observed as an organization that prioritizes people in its operations, fostering a caring and inclusive culture where employees, referred to as Cibeleans, are provided opportunities for growth and meaningful work. Relationships with trade partners are built to ensure sustainable collaborations for patient access to solutions. Innovation is pursued to expand offerings, benefiting stakeholders and contributing to broader societal advancement. The company is noted for its commitment to womens health and internal achievements, operating from Pune, India, with a focus on ethical practices and career development.

Cibeles offers Pharmaceutical Products and Distribution Services.

Cibeles operates through Cibeles Pharmaceuticals Private Limited.

The legal entities of Cibeles currently have 3 directors, including Trushit Pramodray Mehta, Sainath Vramarathnam Iyer, Dheer Dharmesh Shah.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available